Genfit S.A.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- M. Pascal Prigent
- Full Time Employees
- 180
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Parc EurasantE Loos France 59120
- IPO Date
- Mar 27, 2019
- CIK
- 0001757064
- Website
- genfit.com
- Similar Companies
- Business
- Genfit SA (GNFT) is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic and diagnostic solutions for rare and life-threatening liver diseases with high unmet medical needs. Founded in 1999 and headquartered in Loos, France, with a U.S. subsidiary in Cambridge, Massachusetts, the company maintains operations in Europe and North America. Genfit targets primary biliary cholangitis (PBC), acute-on-chronic liver failure (ACLF) and associated conditions including acute decompensation (AD) and hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemias (OA); its therapeutic pipeline features elafibranor (Iqirvo), licensed to Ipsen and approved by the FDA, EMA and MHRA for PBC treatment in 2024 and marketed in several countries, alongside ACLF candidates G1090N (nitazoxanide reformulation), SRT-015, CLM-022 and VS-02-HE with complementary mechanisms of action, and programs in CCA and UCD/OA; diagnostic offerings include NIS2+ for NASH/MASH and TS-01 for blood ammonia levels. In recent developments, Genfit completed a non-dilutive royalty financing agreement with HealthCare Royalty (HCRx) in March 2025 for up to EUR185 million, including an upfront EUR130 million payment to support its pipeline and extend cash runway beyond 2027. The company received a EUR26.5 million milestone payment from Ipsen in 2025 following U.S. pricing and reimbursement for Iqirvo, reported H1 2025 revenue from related milestones and a cash position of EUR107.5 million, and discontinued its VS-01 ACLF program due to safety concerns while advancing other ACLF assets including planned safety data for G1090N by late 2025.
GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
GENFIT : Assemblée Générale Mixte du 15 juin 2026 — modalités de mise à disposition des documents préparatoires
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
GENFIT Announces 2026 Financial Calendar
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
GENFIT Announces Appointment of new Chief Medical Officer
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025